CME: The roadmap to optimizing geographic atrophy care: updates in risk assessment, treatment, and care pathways in late-stage age-related macular degeneration
Activity Description / Statement of Need:
In this online, self-learning activity:
Age-related macular degeneration (AMD) is the most common cause of blindness in individuals over the age of 50 years. In the early stages of disease, vision may be gray, hazy, or distorted. As the disease progresses, retinal deterioration can lead to irreversible, bilateral loss of central vision. In the US alone, an estimated 18.3 million people are living with early-stage ARMD, and 1.5 million people are living with late-stage AMD, representing 11.6% and 0.9% of all adults older than 40 years, respectively. In addition to the burden of disability caused by blindness, AMD is also associated with substantial societal and economic costs. In the US, vision loss and blindness incur an economic burden of $134 billion annually, of which $36 billion is attributable to indirect costs such as loss of productivity, injury, and unemployment.
Target Audience:
The following HCPs: comprehensive ophthalmologists and retinal specialists; physician assistants, and nurse practitioners who practice in ophthalmology; and any other HCPs with an interest in or who clinically encounter patients with AMD.
Commercial Support Disclosure: This program is supported by an educational grant from Apellis Pharmaceuticals.
This activity is free of charge.
Release Date: September 16, 2023 -- Expiration Date: September 16, 2025
Faculty: Joshua Mali, MD
Agenda
|
Faculty introduction, disclosures |
|
Epidemiology of and risk factors for AMD · Statistics – snapshots and trends |
|
Clinical presentation and diagnosis of advanced AMD · Types o Facilitating rapid referral for suspected AMD o Physical examination and imaging o Interpreting imaging results · Burden of disease |
|
Treatment of geographic atrophy (GA) · Supportive care recommendations o Mechanism of action § Role in pathophysiology § Therapeutic targets (C3, C5, etc) o Pegcetacoplan § Randomized clinical trial data: primary and follow-up § Dosing options and selection o Emerging options in development · Emerging therapies: non-complement inhibitors o Indications and identification of treatment candidates o Patient and caregiver counseling o Managing new-onset exudative disease o Bilateral GA management · Patient case(s) |
|
Summary, conclusions, and best practice recap |
Learning Objectives
By the end of the session the participant will be able to:
- Describe the challenges associated with managing geographic atrophy (GA).
- Integrate diagnostic imaging results into the treatment decision-making process for patients with GA.
- Formulate strategies for managing GA, with a focus on preserving vision and quality of life as well as avoiding or mitigating complications.
- Describe mechanistic and clinical features of novel and emerging therapies for GA, and develop a treatment plan.
Accreditation
ACCME Activity #202555132
ScientiaCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians: If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points.
Nurses: The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.
Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosure of Faculty: Joshua Mali, MD, FASRS, Board Certified Ophthalmologist, Manatee Memorial Hospital, has received financial compensation from consulting and/or speakers bureau and/or research grants from Genentech, Sun Pharmaceuticals, Kala Pharmaceuticals, Notal Vision, Samsara Vision, Alimera Sciences, Apellis.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL NOT discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Apellis Pharmaceuticals.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Seeing through the challenges of ocular allergy: Optimization of diagnosis and treatment strategies
The emerging role of biosimilars in ophthalmology
Addressing unmet needs for a common condition: Drugs and device updates in dry eye disease
Glaucoma: best practices and the emerging treatment landscape